Jeffrey Peppercorn MD

Accuracy of Computed Tomography Staging of Mismatch Repair-Deficient Colon Cancer | JCO Oncology Practice PURPOSEThis study assesses the accuracy of radiographic clinical staging by computed tomography (CT) of mismatch repair-deficient (dMMR) colon cancer, given emerging data for neoadjuvant immune…

Woah! 41% of stage I/IIA dMMR colon cancers could be overstaged by CT imaging. May need better ways to upfront stage (MRI, ctDNA?) in the neoadjuvant ICI era. #GIOnc #OncSky #MedSky #JCOOP

ascopubs.org/doi/10.1200/...

Don't Do Me Like That: Promoting Respectful Language in Oncology Research | JCO Oncology Practice

"Beyond respectful language, which is the minimum requirement… [this study] reinforces the broader message about maintaining respect for patients as individuals & ensuring that this is reflected in our words & deeds."
 
@ascocancer.bsky.social
@jco-asco.bsky.social @ethicsdoctorp.bsky.social

OK Computer! Reflections on How Artificial Intelligence Saved Cancer Care | JCO Oncology Practice

Terrific (&entertaining) piece by @jco-asco.bsky.social OP editor @ethicsdoctorp.bsky.social on what he thinks AI could do to transform oncology practice by 2035.

OK Computer! Reflections on How Artificial Intelligence Saved Cancer Care | JCO Oncology Practice ascopubs.org/doi/full/10....

Glory Days: Celebrating Two Decades of Advances in Cancer Care on the 20th Anniversary of JCO Oncology Practice | JCO Oncology Practice

Congrats to ASCO's journal JCO Oncology Practice on your 20-yr anniversary! JCO OP is the unquestioned and authoritative leader on issues of cancer care policy, delivery, & quality ascopubs.org/doi/full/10....

Adequacy of Immune Checkpoint Inhibitor–Associated Thyroid Function Monitoring After Therapy | JCO Oncology Practice PURPOSEImmune checkpoint inhibitor (ICI)-induced thyroid dysfunction is a common endocrine immune-related adverse event. Although rates during therapy are well documented, data on post-treatment thyro...

Adequacy of Immune Checkpoint Inhibitor–Associated Thyroid Function Monitoring After Therapy | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Another great #ASCO25

Also wonderful to see my amazing JCO Oncology Practice colleagues! 📝

Loved Dr. DeMichele’s discussion of SERENA-6 and the incredible CHALLENGE trial data for exercise in colon cancer survivors. 🏃‍♂️

And a chance to hang out for a few hours with my daughter! 🥰

Glory Days: Celebrating Two Decades of Advances in Cancer Care on the 20th Anniversary of JCO Oncology Practice | JCO Oncology Practice ascopubs.org/doi/10.1200/...
A fun collaboration and nostolgic review by those fortunate to serve as Editor-in-Chief over the past 20 years. 🥳

Glory Days: Celebrating Two Decades of Advances in #Cancer Care on the 20th Anniversary of JCO Oncology Practice.

ascopubs.org/doi/full/10....

@ascocancer.bsky.social
#CancerCare #FinancialToxicity #CancerResearch
@ethicsdoctorp.bsky.social @fumikochino.bsky.social @jameabraham.bsky.social

Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline | JCO Oncology Practice ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO G...

Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Patient, Parent, and Oncologist Perspectives and Recommendations on the Right Way to Talk About Prognosis in Advanced Childhood Cancer | JCO Oncology Practice PURPOSEClear prognostic communication is associated with improvements in quality of life and suffering for children with advanced illness. Yet recent evidence demonstrates that pediatric oncologists o...

Patient, Parent, and Oncologist Perspectives and Recommendations on the Right Way to Talk About Prognosis in Advanced Childhood Cancer | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Beyond the Point: Learning From Outcomes After Inpatient Immune Checkpoint Inhibitor Therapy.

ascopubs.org/doi/10.1200/...

@ascopost.bsky.social
@pallonccop.bsky.social
#Immunotherapy #CancerResearch
@ethicsdoctorp.bsky.social

SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low–Tumor Burden Follicular Lymphoma | JCO Oncology Advances

📣 Have something to report on an ongoing clinical trial? #JCOOA now accepting Trials in Progress articles! Read the first one here:

SWOG 2308: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low–Tumor Burden Follicular Lymphoma ascopubs.org/doi/10.1200/...

Reducing Medicare Part D Out-of-Pocket Costs for Specialty Oral Anticancer Drugs Under the Inflation Reduction Act: Highlighting the Benefits of Enrolling in the Medicare Prescription Payment Plan | J... PURPOSEMedicare Part D beneficiaries who do not qualify for low-income subsidies face high out-of-pocket (OOP) costs for brand-name specialty oral anticancer medications (SOAMs). We calculated how OOP...

Reducing Medicare Part D Out-of-Pocket Costs for Specialty Oral Anticancer Drugs Under the Inflation Reduction Act: Highlighting the Benefits of Enrolling in the Medicare Prescription Payment Plan | JCO Oncology Practice ascopubs.org/doi/10.1200/...

An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last | JCO Oncology Practice

An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Humanizing Oncology Care: A Strategic Imperative | JCO Oncology Practice

Humanizing Oncology Care: A Strategic Imperative | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Had a wonderful editorial meeting at @ascocancer.bsky.social headquarters under the leadership of EIC @ethicsdoctorp.bsky.social @acochran12733.bsky.social @fumikochino.bsky.social @ryannipp.bsky.social and others !

Opportunities for Artificial Intelligence in Oncology: From the Lens of Clinicians and Patients | JCO Oncology Practice Much work has been published on artificial intelligence (AI) and oncology, with many focusing on an algorithm perspective. However, very few perspective articles have explicitly discussed the role of ...

Opportunities for Artificial Intelligence in Oncology: From the Lens of Clinicians and Patients | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Facilitated Versus Patient-Directed Advance Care Planning Among Patients With Advanced Cancer: A Randomized Clinical Trial | JCO Oncology Practice PURPOSEGuidelines recommend advance care planning (ACP) to improve patient-centered care near the end of life (EOL), but the optimal approach is unknown. This single-blind, patient-level, randomized c...

Facilitated Versus Patient-Directed Advance Care Planning Among Patients With Advanced Cancer: A Randomized Clinical Trial | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Facilitated Versus Patient-Directed Advance Care Planning Among Patients With Advanced #Cancer: A Randomized Clinical Trial.

ascopubs.org/doi/10.1200/...

@ascopost.bsky.social
@pallonccop.bsky.social
#PallOnc #SuppOnc #CancerCare
@pittpalcare.bsky.social

System-Level Transformations to Increase Patient Participation in Clinical Trials | JCO Oncology Practice PURPOSEOver the course of the COVID-19 pandemic, the Food and Drug Administration allowed cancer clinical trials to make modifications. As policymakers consider sustaining these modifications, underst...

ICYMI: System-Level Transformations to Increase Patient Participation in Clinical Trials ascopubs.org/doi/10.1200/... #JCOOP

Cancer-Related Cognitive Impairment: A Practical Guide for Oncologists | JCO Oncology Practice

Cancer-Related Cognitive Impairment: A Practical Guide for Oncologists | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Now you’ve done it. Sounds like a few weeks with no reviews.

For your listening pleasure:
🎧👂🎙️

Great inaugural Podcast for JCO OP by @fumikochino.bsky.social

On the clinical, academic and very personal aspects of financial toxicity

play.libsyn.com/embed/episod...

JCO Oncology Practice: Vol 21, No 1

The JCO Oncology Practice special issue on financial toxicity in oncology is now online ascopubs.org/toc/op/current. Lots of good articles including a narrative review from Peppercorn (@ethicsdoctorp.bsky.social) et al on validated tools to measure FT ascopubs.org/doi/full/10....

Financial Toxicity in Older Adults With #Cancer and Their Caregivers.

ascopubs.org/doi/abs/10.1...

@ascocancer.bsky.social @ascopost.bsky.social
#FinancialToxicity #GeriOnc #PallOnc
@melissaloh.bsky.social

JCO Oncology Practice: Vol 21, No 1

🚨 The #FinancialToxicity special issue of JCO OP is LIVE today! 🚨

We hope these papers will encourage the next gen of researchers to generate, evaluate, & disseminate patient-centered, high-quality, evidence-based medicine & policy solutions to close the affordability gap!

ascopubs.org/toc/op/21/1

ascopubs.org/journal/op

Out today! 🤩 JCO Oncology Practice Special Issue dedicated to the challenge of Financial Toxicity in Oncology.

Great work by @fumikochino.bsky.social @ryannipp.bsky.social
pulling this issue together.

Financial Toxicity in #Cancer Care: Where Are We, and How Did We Get Here?
Introduction to a Special Series.

ascopubs.org/doi/10.1200/...

@ascocancer.bsky.social @ascopost.bsky.social
#FinancialToxicity #PallOnc #CostsOfCare #GeriOnc
@fumikochino.bsky.social @ethicsdoctorp.bsky.social

Current Trends in Treating Malignant Pleural Effusion: Evidence, Guidelines, and Best Practice Recommendations | JCO Oncology Practice Malignant pleural effusion (MPE) is common in individuals with cancer and typically reflects advanced disease. Most cases are symptomatic, with dyspnea and pain having a severe effect on the patient's...

New review from #JCOOP: Current Trends in Treating Malignant Pleural Effusion: Evidence, Guidelines, and Best Practice Recommendations #openaccess #oncsky #JCOJournals ascopubs.org/doi/10.1200/...